AU6567800A - Substances and agents for positively influencing collagen - Google Patents

Substances and agents for positively influencing collagen

Info

Publication number
AU6567800A
AU6567800A AU65678/00A AU6567800A AU6567800A AU 6567800 A AU6567800 A AU 6567800A AU 65678/00 A AU65678/00 A AU 65678/00A AU 6567800 A AU6567800 A AU 6567800A AU 6567800 A AU6567800 A AU 6567800A
Authority
AU
Australia
Prior art keywords
substances
agents
positively influencing
strias
wrinkles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65678/00A
Other languages
English (en)
Inventor
Alfred Schmidt
Heinrich Wieland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7918298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU6567800(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of AU6567800A publication Critical patent/AU6567800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)
AU65678/00A 1999-08-13 2000-07-28 Substances and agents for positively influencing collagen Abandoned AU6567800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19938421 1999-08-13
DE19938421 1999-08-13
PCT/EP2000/007315 WO2001012206A2 (de) 1999-08-13 2000-07-28 Soja-glycine extracten und aromatase-hemendern zur positiven beeinflussung von kollagen

Publications (1)

Publication Number Publication Date
AU6567800A true AU6567800A (en) 2001-03-13

Family

ID=7918298

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65678/00A Abandoned AU6567800A (en) 1999-08-13 2000-07-28 Substances and agents for positively influencing collagen

Country Status (9)

Country Link
US (2) US8278291B1 (es)
EP (1) EP1253966B1 (es)
AT (1) ATE506986T1 (es)
AU (1) AU6567800A (es)
BR (1) BR0013272B1 (es)
CA (1) CA2380940C (es)
DE (1) DE50016101D1 (es)
MX (1) MXPA02001547A (es)
WO (1) WO2001012206A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
PL370080A1 (en) * 2001-10-10 2005-05-16 Pharmacia Italia Spa Methods for preventing and treating bone loss with steroid compounds
AU2003213958A1 (en) * 2002-04-03 2003-10-13 Jencap Research Ltd. Female birth control method
US6866856B2 (en) * 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
FR2861293B1 (fr) * 2003-10-22 2008-10-17 Greenpharma Sas Composition pour prevenir ou traiter des affections resultant d'un processus de mort cellulaire comprenant une lactone sesquiterpenique
DE102008012988A1 (de) 2008-03-07 2009-09-10 S.W. Patentverwertungs Ltd. Zusammensetzung und Verwendungen zur Beeinflussung des Haarwachstums
EP2670382B1 (de) * 2011-01-31 2018-07-18 LUCOLAS-M.D. Ltd. Kosmetische verwendung
US11850451B2 (en) 2011-01-31 2023-12-26 Lucolas-M.D. Ltd. Cosmetic compositions and methods for improving skin conditions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3338212C2 (de) * 1983-10-18 1995-05-18 Schering Ag 1-Methyl-androsta-1,4,6-trien-3,17-dione, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DK0943328T3 (da) * 1989-07-07 2004-10-18 Endorech Inc Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi
DE3926365A1 (de) * 1989-08-04 1991-02-07 Schering Ag Cycloalkylenazole, verfahren zu deren herstellung, pharmazeutische praeparate, die diese enthalten sowie ihre verwendung zur herstellung von arzneimitteln
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
WO1994009764A1 (en) * 1992-10-27 1994-05-11 Nippon Kayaku Kabushiki Kaisha Use of non steroidal anti estrogens for autoimmune diseases
US5494899A (en) 1993-04-07 1996-02-27 Oklahoma Medical Research Foundation Selective regulation of B lymphocyte precursors by hormones
US5587392A (en) 1994-05-27 1996-12-24 Mochida Pharmaceutical Co., Ltd. Azolyl methyl phenyl derivatives having aromatase inhibitory activity
NZ292940A (en) * 1994-09-14 1998-12-23 Univ Sheffield Use of an aromatase inhibitor and/or an androgen receptor anatonist as a cosmetic agent to reduce hair loss
US5582832A (en) * 1995-06-06 1996-12-10 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Compositions for topical application to skin
JPH11508241A (ja) * 1995-06-07 1999-07-21 カロ バイオ エービー 甲状腺ホルモンまたは甲状腺ホルモン様化合物に関する新規な使用
DE59703511D1 (de) * 1996-03-29 2001-06-13 S W Patentverwaltungs Ges M B Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der "cellulite"
US6471972B1 (en) * 1996-11-07 2002-10-29 Lvmh Recherche Cosmetic treatment method for fighting against skin ageing effects
FR2779059B1 (fr) * 1998-05-29 2004-09-10 Guerlain Procede de traitement cosmetique pour lutter contre les effets du vieillissement cutane; nouvelles compositions cosmetiques pour sa mise en oeuvre
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
US6071526A (en) * 1997-03-27 2000-06-06 S.W. Patentverwertungs Ges M.B. H. Cosmetic or cosmetic product for firming and soothing the skin in particular in the case of cellulite
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
US6054446A (en) * 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
FR2779058B1 (fr) * 1998-05-29 2003-02-21 Dior Christian Parfums Utilisation d'au moins une saponine ou un sapogenol cosmetiquement acceptable, comme agent cosmetique destine a augmenter la quantite de collagene iv dans la jonction dermo-epidermique
PT1083929E (pt) * 1998-06-05 2007-05-31 Nutramax Lab Inc Utilização de agentes anabólicos, agentes anti-catabólicos, agentes antioxidantese e analgésicos para protecção, tratamento e reparação de tecidos conjuntivos em seres humanos e animais.
US6461627B1 (en) * 1998-10-09 2002-10-08 Kabushiki Kaisha Yakult Honsha Skin preparations for external use
US20030211177A1 (en) * 2001-03-16 2003-11-13 Pineda Edwin H Method and composition for treatment and prevention of alopecia
US6920883B2 (en) * 2001-11-08 2005-07-26 Arthrocare Corporation Methods and apparatus for skin treatment

Also Published As

Publication number Publication date
CA2380940C (en) 2013-06-25
BR0013272A (pt) 2002-04-23
ATE506986T1 (de) 2011-05-15
DE50016101D1 (de) 2011-06-09
WO2001012206A2 (de) 2001-02-22
EP1253966B1 (de) 2011-04-27
BR0013272B1 (pt) 2013-10-15
US8278291B1 (en) 2012-10-02
CA2380940A1 (en) 2001-02-22
EP1253966A2 (de) 2002-11-06
WO2001012206A3 (de) 2002-08-01
MXPA02001547A (es) 2002-07-02
US20070148123A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
WO2002058706A3 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
CA2069483A1 (en) Steroid sulphatase inhibitors
KR970706002A (ko) 남성의 상대적 안드로겐 결핍증 치료를 위한 약제의 제조에 있어서 아로마타제 억제제의 용도(Use of Aromatase Inhibitors in the Preparation of a Drug for Treating a Relative Androgen Deficiency in Men)
NZ524104A (en) Exemestane as chemopreventing agent
AU6567800A (en) Substances and agents for positively influencing collagen
FR2775897B1 (fr) Utilisation d'amidon comme actif destine au traitement et/ou a la prevention de l'apparition des signes du vieillissement dans une composition cosmetique ou dermatologique
DE69629570D1 (de) 3'utr des menschliches prohibitin-gens
AU2002220803A1 (en) Composition, in particular cosmetic, containing 7-hydroxy dhea and/or 7-keto dhea and at least an isoflavonoid
ATE526944T1 (de) Selbstbräunungszusammensetzungen die cholesterolsulfat und dha enthalten
DE60017281D1 (de) Nomegestrol acetat und estrogen enthaltende zusammensetzung und ihre verwendung
ES2191358T3 (es) Uso de un inhibidor de aromatasa en el tratamiento de una disminucion en la relacion de androgenos a estrogenos y de la disinergia entre el detrusor y el esfinter uretral en hombres y metodos para estudiar la disinergia en roedores machos.
ZA985993B (en) Pharmaceutical compositions
CO5060466A1 (es) Metodo de reduccion o prevencion del mal olor
ES2136581A1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
MXPA02009744A (es) Uso de fulvestrant en el tratamiento de cancer resistente de mama.
GB9422777D0 (en) Assay
TNSN99138A1 (fr) Une composition antioxydante, cytostatique et a support energetique qui ameliore l'utilisation metabolique du glucose
GB9814646D0 (en) Method of reducing or preventing malodour
TR200101109T2 (tr) Geliştirilmiş damar daraltan tesirliliğe sahip bulunan flutikazon losyonu
FR2787028B1 (fr) Utilisation du riluzole dans le traitement des traumatismes acoustiques
Buyon et al. Recommendations for exogenous estrogen to prevent glucocorticoid-induced osteoporosis in premenopausal women with oligo-or amenorrhea: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis
NZ514691A (en) Method to type prion proteins
EP1321146A3 (en) Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
达建 et al. Studies on the Phenotypes and Frequencies of ALADH in Nanjing Area

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase